Tuesday, April 11, 2017 6:51:47 AM
Hi,
On November 2, 2016, we entered into a securities purchase agreement (“Purchase Agreement”) with Sabby Healthcare Master Fund, Ltd. and Sabby Volatility Master Fund, Ltd.
(collectively, “Selling Securityholders”).
Pursuant to the Purchase Agreement, the Selling Securityholders agreed to purchase, in a private placement (the “Private Placement”), 2,272,727 shares of our Common Stock, and Warrants. Each Warrant will be exercisable for one share of our Common Stock and will have the same terms as our existing publicly traded warrants that are currently listed on The NASDAQ Capital Market under the symbol “APDNW”, with an exercise price of $3.50 and an expiration date of November 20, 2019. The aggregate gross proceeds of the Private Placement were approximately $5.0 million before deducting the placement agents’ fee and other placement expenses. The price per share of Common Stock was $2.49 and the price per Warrant was $.01. The Private Placement closed on November 7, 2016 (the “Closing Date”).
Further, we agreed not to effect any issuance of Common Stock or securities convertible into Common Stock involving
a” Variable Rate Transaction,”
(produce enough shares at whatever
price to get Sabbys’ collateral back to $5 million)
while the Selling Securityholders hold any Warrants.
(Sabby can dispose of the warrants any way it chooses: Give them to
charity if they want to.)
In addition, pursuant to the Purchase Agreement, upon any Subsequent Financing, as defined in the Purchase Agreement, during the period ending on the nine (9) (August or Sptember) month anniversary of the Effective Date, the Selling Securityholders shall have the right to participate in up to an amount equal to 25% of the Subsequent Financing; provided that no Selling Securityholders shall have such participation right to the extent that after giving effect to such participation, such Selling Securityholders (together with such Selling Securityholders’s affiliates, and any persons acting as a group together with such Selling Securityholders or its affiliates) would beneficially own in excess of 9.99% of the Common Stock outstanding immediately after giving effect to the Subsequent Financing.
If Sabby triggers the variable rate option within the 9 month
period, the floodgates are open.
Adnas would issue at least 4X the number of shares necessary
to make Sabby whole, yet keep their ownership less than 10%.
They can then repeat the process as necessary, using the variable
rate option to destroy the share price and take control.
Sabby owns Adnas. Unless Adnas can put Sabby in the money,
they are done.
This is my lay understanding of the deal.
My hope is that Adnas has blockbuster news very soon.
On November 2, 2016, we entered into a securities purchase agreement (“Purchase Agreement”) with Sabby Healthcare Master Fund, Ltd. and Sabby Volatility Master Fund, Ltd.
(collectively, “Selling Securityholders”).
Pursuant to the Purchase Agreement, the Selling Securityholders agreed to purchase, in a private placement (the “Private Placement”), 2,272,727 shares of our Common Stock, and Warrants. Each Warrant will be exercisable for one share of our Common Stock and will have the same terms as our existing publicly traded warrants that are currently listed on The NASDAQ Capital Market under the symbol “APDNW”, with an exercise price of $3.50 and an expiration date of November 20, 2019. The aggregate gross proceeds of the Private Placement were approximately $5.0 million before deducting the placement agents’ fee and other placement expenses. The price per share of Common Stock was $2.49 and the price per Warrant was $.01. The Private Placement closed on November 7, 2016 (the “Closing Date”).
Further, we agreed not to effect any issuance of Common Stock or securities convertible into Common Stock involving
a” Variable Rate Transaction,”
(produce enough shares at whatever
price to get Sabbys’ collateral back to $5 million)
while the Selling Securityholders hold any Warrants.
(Sabby can dispose of the warrants any way it chooses: Give them to
charity if they want to.)
In addition, pursuant to the Purchase Agreement, upon any Subsequent Financing, as defined in the Purchase Agreement, during the period ending on the nine (9) (August or Sptember) month anniversary of the Effective Date, the Selling Securityholders shall have the right to participate in up to an amount equal to 25% of the Subsequent Financing; provided that no Selling Securityholders shall have such participation right to the extent that after giving effect to such participation, such Selling Securityholders (together with such Selling Securityholders’s affiliates, and any persons acting as a group together with such Selling Securityholders or its affiliates) would beneficially own in excess of 9.99% of the Common Stock outstanding immediately after giving effect to the Subsequent Financing.
If Sabby triggers the variable rate option within the 9 month
period, the floodgates are open.
Adnas would issue at least 4X the number of shares necessary
to make Sabby whole, yet keep their ownership less than 10%.
They can then repeat the process as necessary, using the variable
rate option to destroy the share price and take control.
Sabby owns Adnas. Unless Adnas can put Sabby in the money,
they are done.
This is my lay understanding of the deal.
My hope is that Adnas has blockbuster news very soon.
Recent BNBX News
- BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value • Business Wire • 04/20/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:09:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:08:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:07:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:06:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:06:14 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 03/25/2026 12:09:48 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/24/2026 08:15:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 08:06:00 PM
- BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform • Business Wire • 03/18/2026 12:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/12/2026 09:24:23 PM
- BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers • Business Wire • 02/24/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:16:58 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/13/2026 07:49:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2026 09:32:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 09:11:07 PM
- BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director • Business Wire • 02/05/2026 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/30/2026 09:06:16 PM
- Digital Asset Virtual Investor Conference: Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 01/28/2026 01:35:00 PM
- BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th • Business Wire • 01/27/2026 01:00:00 PM
- BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th • GlobeNewswire Inc. • 01/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2026 09:10:46 PM
- BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA™ Order • Business Wire • 01/05/2026 01:01:00 PM
